Esperion Therapeutics (ESPR) Misses Q1 EPS by 8c

Esperion Therapeutics (NASDAQ: ESPR) reported Q1 EPS of ($0.56), $0.08 worse than the analyst estimate of ($0.48).

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• KeyBanc Sees 'A Potential Catalyst for Earnings Growth and Value Creation' for Acadia Realty Trust (AKR)
• KB Home (KBH) PT Lowered to $50 at RBC Capital